ERBB2 and cancer: Mittendorf et al[14] found that among the patients who did not achieve pCR after neoadjuvant trastuzumab treatment, there were 25 patients with sufficient residual cancer tissue to retest HER2 expression status, and 8 (32%) of them were negative.